DEA June 29 Hearing Could Reshape Cannabis: What to Expect in 2026

The Most Important Cannabis Hearing in a Generation

On June 29, 2026, at 9:00 a.m. Eastern Time, the Drug Enforcement Administration will convene an administrative hearing at its facility at 700 Army Navy Drive in Arlington, Virginia, that could fundamentally alter the legal status of cannabis in the United States. The hearing, which is scheduled to conclude no later than July 15 (with a recess from July 3 to July 6 for Independence Day), will evaluate whether all marijuana — including recreational cannabis in adult-use states — should be rescheduled from Schedule I to Schedule III of the Controlled Substances Act.

This is not a theoretical exercise. The federal government has already taken the extraordinary step of moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III through a final order issued on April 23, 2026. The June 29 hearing represents the next logical step: determining whether the broader universe of cannabis products deserves the same treatment.

The deadline for interested parties to submit written notices of intent to participate is May 28, 2026 — just days away. The tight timeline reflects the expedited nature of this proceeding, which the DEA has fast-tracked compared to the glacial pace that has historically characterized federal marijuana policy.

What Rescheduling Would Mean

The difference between Schedule I and Schedule III is enormous, and understanding it is essential to grasping what is at stake in the June hearing.

Schedule I substances are defined as having a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. Cannabis has occupied this classification since 1970, alongside heroin and LSD. This classification has been the foundation of federal marijuana prohibition, driving criminal penalties, blocking research, and creating the legal conflict between federal and state cannabis laws.

Schedule III substances are considered to have a moderate to low potential for physical and psychological dependence. Examples include ketamine, anabolic steroids, and testosterone. Importantly, Schedule III substances can be prescribed by doctors, researched more freely, and produced and distributed under regulated conditions.

For the cannabis industry, broader rescheduling to Schedule III would have cascading effects. The elimination of Section 280E tax penalties, which prevent cannabis businesses from deducting ordinary business expenses, would immediately improve the financial viability of thousands of companies. Access to banking services, which has been severely restricted by cannabis's Schedule I status, would become significantly easier. Research institutions could study cannabis with fewer bureaucratic barriers, accelerating the development of evidence-based medical applications.

What the Hearing Will Address

The hearing will focus on the scientific and medical evidence regarding marijuana's pharmacological properties, its potential for abuse, and its currently accepted medical use. The DEA will hear testimony from researchers, medical professionals, industry representatives, law enforcement officials, and public health advocates.

The central question is straightforward but laden with decades of political and cultural baggage: does the scientific evidence support treating cannabis the same as heroin, or is its pharmacological profile more consistent with substances like ketamine or codeine?

The evidence on this question has shifted dramatically in recent years. Over 100 cannabis studies have been published in 2026 alone, spanning pain relief, cancer treatment, sleep disorders, metabolic health, and neurological conditions. The consensus among most medical researchers is that cannabis's Schedule I classification is scientifically indefensible, though opinions vary on whether Schedule III is the appropriate alternative or whether cannabis warrants an even lower classification or complete descheduling.

The Arguments For and Against

Proponents of broader rescheduling will likely emphasize several key points. The growing body of clinical evidence supporting medical applications of cannabis undermines the Schedule I requirement that a substance have "no currently accepted medical use." The 24 states plus the District of Columbia that have legalized adult-use cannabis, along with the 38 states with medical programs, demonstrate broad societal acceptance that contradicts Schedule I treatment. The economic benefits of rescheduling — including tax fairness, banking access, and research funding — would strengthen legal markets and reduce the influence of illegal operations.

Opponents will likely argue for caution. Some law enforcement organizations are expected to raise concerns about the potential for increased use, particularly among young people, if federal restrictions are loosened. Certain public health groups may argue that more research is needed before such a significant policy change. There may also be arguments about the practical challenges of regulating a Schedule III substance that is used recreationally in some states but remains available only for medical use in others.

The Political Context

The hearing does not occur in a political vacuum. President Trump's December 2025 executive order initiating the rescheduling process was widely interpreted as a populist move designed to appeal to the growing majority of Americans who support cannabis legalization. The April 2026 final order moving medical cannabis to Schedule III demonstrated that the administration is willing to follow through on that initiative.

However, the broader rescheduling question is more politically complex. While medical cannabis enjoys near-universal public support, recreational cannabis remains more divisive in some constituencies. The hearing process provides a framework for the DEA to evaluate the evidence on its merits, but the eventual decision will inevitably be influenced by political considerations as well.

Congress is also watching closely. Several cannabis banking and reform bills have stalled in the Senate over the past several years. A positive outcome at the June hearing could provide momentum for legislative action, while a negative outcome could set back reform efforts for years.

What Industry Leaders Are Saying

Cannabis industry stakeholders are approaching the hearing with cautious optimism. The fact that the hearing is happening at all — and on an expedited timeline — is seen as a positive signal. The DOJ's willingness to move medical cannabis to Schedule III is viewed as establishing a precedent and a framework that could be extended to broader rescheduling.

However, experienced industry observers caution against expecting immediate results. Administrative hearings generate recommendations, not binding decisions. Even if the hearing produces a recommendation for broader rescheduling, the DEA must then issue a proposed rule, accept public comments, and publish a final rule. This process could take months or even years.

There is also uncertainty about the scope of any potential rescheduling. The hearing could result in a recommendation to reschedule all cannabis to Schedule III, to reschedule only certain products or potency levels, or to maintain the current classification. The range of possible outcomes is wide.

Preparing for Multiple Scenarios

Smart cannabis businesses are preparing for multiple outcomes rather than betting on a single result. Companies are restructuring their tax strategies to take advantage of 280E relief that is already available for medical operations under Schedule III while maintaining contingency plans in case broader rescheduling does not materialize.

Investors are similarly hedging their positions. Cannabis stocks have seen increased trading volume and modest price increases since the April rescheduling order, but the market appears to be pricing in a moderate rather than aggressive expectation for the June hearing outcome.

For consumers, the practical impact of the hearing will depend heavily on where they live. In states with established legal markets, broader rescheduling would likely mean lower prices (as businesses pass along tax savings), better product selection (as research and development funding increases), and potentially wider distribution channels. In states without legal markets, the hearing outcome could influence whether and when legalization occurs, but would not directly create retail access.

The Bigger Picture

Regardless of the specific outcome of the June 29 hearing, the fact that the United States is conducting a formal, expedited evaluation of marijuana's Schedule I status represents a watershed moment in American drug policy. For more than 50 years, cannabis has been classified alongside the most dangerous substances known to pharmacology. The hearing is an explicit acknowledgment that this classification no longer reflects scientific consensus, medical practice, or public opinion.

Whatever happens in Arlington, Virginia, over those two weeks in late June and early July, the direction of travel is clear. The question is no longer whether federal cannabis policy will change, but how quickly and how comprehensively. The June 29 hearing is the next major signpost on that journey.

Looking for a licensed shop near you? Browse Budpedia's directory of verified cannabis dispensaries to find a dispensary in your area.